Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Biomedical research in 2013 saw some dramatic developments, with unprecedented government action in the US ranging from the budget sequester in the spring to a dramatic government shutdown in autumn. But throughout the year, bright spots in science around the globe continued to dazzle, including multimillion-dollar partnerships to advance drug discovery and the go-ahead for highly anticipated trials of regenerative medicine.
As immunotherapies and even newer strategies such as antisense therapy march ahead, the drug development pipeline took an interesting turn this year. Here, we look back at the compounds that made the cut, as well as those that got cut.
From the microbiome to the microenvironment, certain areas of biomedicine saw fast-paced discovery this year. Here's a rundown of the papers that helped these fields advance quickly in 2013.
Our list of newsmakers this year includes everyone from thought leaders with brainy plans for the future to individuals who influenced rules and regulations—even from beyond the grave.